Figure 3
From: NEK9-dependent proliferation of cancer cells lacking functional p53
Growth inhibition of p53-mutant xenograft by NEK9 siRNA.
(A) Schedule of administration of NEK9 siRNA into SW480 or HCT 116 xenografts. Arrows show the days on which injections of siRNA/in vivo–jetPEI complex were administered. (B) SW480 and HCT 116 cells were inoculated into the backs of nude mice (n = 4) and siRNAs (NEK9 or negative control [NC]) in complex with drug-delivery carrier were injected on the specified days (arrows at the bottom of the graph). Tumor volume is expressed as a percentage (%) relative to the volume at the time of the first siRNA injection (day 0). Error bars indicate SD (n = 4). A left graph indicates tumor growth of p53 WT HCT 116 cells. A right graph is p53 mutant SW480. (C) Representative images of mice with xenograft tumors are shown on the left (HCT 116) and right (SW480). (D) Comparison of xenograft tumors injected with NC (upper panel) and NEK9 siRNA (lower panel).
